VIA
CRSP icon

Vantage Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Vantage Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$9K Hold
200
– – ﹤0.01% 547
2018
Q2 		$12K Buy
+200
New +$11.4K ﹤0.01% 499

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vantage Investment Advisors's CRSP Position: Q3 2018 in Review

Vantage Investment Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2018 at 200 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #547.

Vantage Investment Advisors first reported a position in CRSP in Q2 2018 and has held it in 2 quarters since. The position peaked at $12K in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Vantage Investment Advisors held 200 shares of CRISPR Therapeutics worth $9K as of Q3 2018.
  • Vantage Investment Advisors left its CRISPR Therapeutics share count unchanged in Q3 2018.
  • CRISPR Therapeutics made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #547 holding.
  • Vantage Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • Vantage Investment Advisors's CRISPR Therapeutics position peaked at $12K in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.